Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 5/20 | 0.51 |
| ▸ | MEN1 | O00255 | 3/20 | 0.50 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.47 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.44 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.44 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.40 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | ELANE | P08246 | 1/20 | 0.38 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.37 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1951070 | 0.87 | KMT2A (0.64) | KMT2AMEN1RIPK1DDB1CRBN | |
| SCHEMBL14016406 | 0.87 | KMT2A (0.56) | KMT2AMEN1RIPK1DDB1CRBN | |
| SCHEMBL21225566 | 0.82 | KMT2A (0.46) | KMT2AMEN1RIPK1DDB1CRBN | |
| SCHEMBL21225405 | 0.81 | KMT2A (0.51) | KMT2AMEN1RIPK1DDB1CRBN | |
| SCHEMBL17352353 | 0.78 | KMT2A (0.32) | KMT2ADDB1CRBNCYP2D6TSHR | |
| SCHEMBL21228069 | 0.73 | GAA (0.46) | KMT2AMEN1RIPK1DDB1CRBN | |
| SCHEMBL21228085 | 0.73 | KMT2A (0.43) | KMT2AMEN1RIPK1DDB1CRBN | |
| SCHEMBL25291191 | 0.72 | CYP2D6 (0.51) | KMT2AMEN1CYP2D6TSHRCYP3A4 | |
| SCHEMBL19838504 | 0.71 | RIPK1 (0.51) | KMT2AMEN1RIPK1DDB1CRBN | |
| SCHEMBL15937141 | 0.71 | PIK3CD (0.39) | POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10253032-B2 | Spiro-lactam NMDA receptor modulators and uses thereof | APTINYX INC. (US) | 2019-04-09 | — | — | US | disclosed |
| EP-2951186-B1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | APTINYX INC (US) | 2018-07-25 | — | — | EP | disclosed |
| EP-2951186-B1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | APTINYX INC (US) | 2018-07-25 | — | — | EP | disclosed |
| US-20180155354-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | TENACIA BIOTECHNOLOGY (HONG KONG) CO., LIMITED (HK) | 2018-06-07 | — | — | US | disclosed |
| US-20180155354-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | TENACIA BIOTECHNOLOGY (HONG KONG) CO., LIMITED (HK) | 2018-06-07 | — | — | US | disclosed |
| US-9738650-B2 | Spiro-lactam NMDA receptor modulators and uses thereof | APTINYX INC. (US) | 2017-08-22 | — | — | US | disclosed |
| US-9738650-B2 | Spiro-lactam NMDA receptor modulators and uses thereof | APTINYX INC. (US) | 2017-08-22 | — | — | US | disclosed |
| US-9738650-B2 | Spiro-lactam NMDA receptor modulators and uses thereof | APTINYX INC. (US) | 2017-08-22 | — | — | US | disclosed |
| US-20150376195-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | TENACIA BIOTECHNOLOGY (HONG KONG) CO., LIMITED (HK) | 2015-12-31 | — | — | US | disclosed |
| US-20150376195-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | TENACIA BIOTECHNOLOGY (HONG KONG) CO., LIMITED (HK) | 2015-12-31 | — | — | US | disclosed |
| US-20150376195-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | TENACIA BIOTECHNOLOGY (HONG KONG) CO., LIMITED (HK) | 2015-12-31 | — | — | US | disclosed |
| WO-2014120789-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | NAUREX, INC. (US) | 2014-08-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10253032-B2 | Spiro-lactam NMDA receptor modulators and uses thereof | GRIN1, GRIN2A, GRIN3A | KMT2A 1466/4885MEN1 2012/4885RIPK1 965/4885 |
| US-20150376195-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | GRIN1, GRIN2A, GRIN3A | KMT2A 1466/4885MEN1 2012/4885RIPK1 965/4885 |
| US-20180155354-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | GRIN1, GRIN2A, GRIN3A | KMT2A 1466/4885MEN1 2012/4885RIPK1 965/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.